Literature DB >> 7617661

Immunophenotypic characterization of infiltrating polynuclear and mononuclear cells in childhood brain tumors.

B Bodey1, B Bodey1, S E Siegel.   

Abstract

During a systematic cell surface antigen expression profile analysis of 76 primary childhood brain tumors (34 medulloblastomas/primitive neuroectodermal tumors and 42 astrocytomas), we employed the following library of monoclonal antibodies (MoABs): anti-Leu-2/a; anti-Leu-3/a; anti-Leu-M5; anti-Leu-11b; anti-HLA-A, -B, -C; anti-HLA-DR; anti-HLe-1 (leukocyte common antigen); and UJ 308. The MoABs identified the expression of various leukocyte-associated, lymphocyte cell line differentiated, cell surface antigens in childhood brain tumors. The antigens were detected with an indirect, biotin-streptavidin-conjugated alkaline phosphatase (AP) immunocytochemical technique. Leu-2/a+ cells comprise the significant CD8+ cytotoxic T-lymphocyte (CTL) population of the tumor-infiltrating lymphocytes. CTLs are major histocompatibility complex (MHC) class I restricted, tumor-associated antigen-specific, cytotoxic cells and were identified in 58 of 76 (76.32%) brain tumors. CTLs usually represented 1-10% of all cells, but in some cases 30-44% of the cells were CD8+. CD4+, MHC class II restricted helper lymphocytes, detected with MoAB anti-Leu-3/a, were present in 65 of 76 (85.53%) brain tumors. Usually 1-10% of the observed cells reacted with MoAB anti-Leu 3/a. Macrophages (Leu-M5 antigen-positive cells) were expressed in 74 of 76 (97.37%) brain tumors. Their number also represented 1-10% of all observed cells in the frozen brain tumor sections. All 76 (100%) brain tumors contained cells that reacted positively with MoABs anti-HLA-A, -B, -C and anti-HLA-DR, demonstrating a strong MHC class I restriction of the tumor cell population and an overall leukocyte antigen expression.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617661

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

1.  Characterization of signaling function and expression of HLA class I molecules in medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Elisabeth J Rushing; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Neurooncol       Date:  2010-09-02       Impact factor: 4.130

Review 2.  Medulloblasoma: challenges for effective immunotherapy.

Authors:  Adam M Sonabend; Alfred T Ogden; Lisa M Maier; David E Anderson; Peter Canoll; Jeffrey N Bruce; Richard C E Anderson
Journal:  J Neurooncol       Date:  2011-12-16       Impact factor: 4.130

3.  Immunological low-dose radiation modulates the pediatric medulloblastoma antigens and enhances antibody-dependent cellular cytotoxicity.

Authors:  Arabinda Das; Daniel McDonald; Stephen Lowe; Amy-Lee Bredlau; Kenneth Vanek; Sunil J Patel; Samuel Cheshier; Ramin Eskandari
Journal:  Childs Nerv Syst       Date:  2016-12-09       Impact factor: 1.475

4.  A novel role of HLA class I in the pathology of medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Bhargavi Rajan; Elisabeth J Rushing; Mi Rim Choi; Brian R Rood; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Transl Med       Date:  2009-07-12       Impact factor: 5.531

5.  Selective cancer-germline gene expression in pediatric brain tumors.

Authors:  Joannes F M Jacobs; Oliver M Grauer; Francis Brasseur; Peter M Hoogerbrugge; Pieter Wesseling; Corrie E Gidding; Mandy W M M van de Rakt; Carl G Figdor; Pierre G Coulie; I Jolanda M de Vries; Gosse J Adema
Journal:  J Neurooncol       Date:  2008-04-09       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.